Relief Therapeutics/NeuroRx's Aviptadil Promise In COVID-19-Associated Respiratory Failure
Randomized Trial Results Expected Later This Quarter
Although top-line efficacy results from a small study in critically ill patients with COVID-19 suggest there are therapeutic benefits associated with Relief Therapeutics/NeuroRx’s RLF-100 (aviptadil), further data are awaited from the results of a randomized clinical trial, expected later this year.
